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A B S T R A C TObjectives: The primary objective was to assess the cost-
effectiveness of new oral anticoagulants compared with warfarin
in patients with nonvalvular atrial fibrillation. Secondary objectives
related to assessing the cost-effectiveness of new oral anticoagu-
lants stratified by center-specific time in therapeutic range, age, and
CHADS2 score. Methods: Cost-effectiveness was assessed by the
incremental cost per quality-adjusted life-year (QALY) gained. Anal-
ysis used a Markov cohort model that followed patients from
initiation of pharmacotherapy to death. Transition probabilities
were obtained from a concurrent network meta-analysis. Utility
values and costs were obtained from published data. Numerous
deterministic sensitivity analyses and probabilistic analysis were
conducted. Results: The incremental cost per QALY gained for
dabigatran 150 mg versus warfarin was $20,797. Apixaban produced
equal QALYs at a higher cost. Dabigatran 110 mg and rivaroxaban
were dominated by dabigatran 150 mg and apixaban. Results weresee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.009
ottawaheart.ca.
ndence to: George A. Wells, Cardiovascular Researc
Canada K1Y 4W7.sensitive to the drug costs of apixaban, the time horizon adopted,
and the consequences from major and minor bleeds with dabiga-
tran. Results varied by a center’s average time in therapeutic range, a
patient’s CHADS2 score, and patient age, with either dabigatran 150
mg or apixaban being optimal. Conclusions: Results were highly
sensitive to patient characteristics. Rivaroxaban and dabigatran 110
mg were unlikely to be cost-effective. For different characteristics,
apixaban or dabigatran 150 mg were optimal. Thus, the choice
between these two options may come down to the price of apixaban
and further evidence on the impact of major and minor bleeds with
dabigatran.
Keywords: anticoagulants, atrial fibrillation, cardiovascular, cost-
effectiveness, warfarin.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Approximately 250,000 Canadians are affected by atrial fibrilla-
tion (AF) [1]. Patients with AF have a substantially increased risk
of death and have higher annual rates of mortality [1,2]. AF and
stroke are more common among the elderly [3,4].
Preventing events such as stroke is an important part of
managing patients with AF. Antithrombotic strategies for
patients with AF include anticoagulant drugs, vitamin K antag-
onists , such as warfarin, and antiplatelet agents, such as aspirin.
Vitamin K antagonists reduce the risk of stroke in patients with
AF but are associated with some drawbacks, including a need for
laboratory monitoring, an increased risk of bleeding complica-
tions, and several food and drug interactions [5,6]. Recently, a
number of new oral anticoagulants (NOACs) have been approved,
including dabigatran, a direct thrombin inhibitor, and the direct
factor Xa inhibitors, rivaroxaban and apixaban.While dabigatran, apixaban, and rivaroxaban have been dem-
onstrated to be effective in preventing stroke/systemic embolism
in patients with AF, the comparative cost-effectiveness of these
NOACs is not clear. Currently, treatment with warfarin including
regular international normalized ratio monitoring costs less than
$300 per annum. The new anticoagulants examined in this study
cost more than $1100 per annum. Thus, the cost-effectiveness of
these agents will depend on the balance between the increased
benefits in terms of stroke prevention, the effect on bleeding
rates, and the increased drug costs [7–11]. This analysis is the first
systematic, independent analysis of the cost-effectiveness of all
three NOACs in comparison to warfarin in patients with
nonvalvular AF.
This study involved incorporating data from a concurrent
systematic review into an economic model of NOAC use in
Canada [12]. The primary objective was to assess the cost-
effectiveness of NOACs compared with warfarin—with additionalSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 8 – 5 0 6 499stratified analysis based on center-specific time in therapeutic
range (TTR), age, and CHADS2 score.Methods
Study Objective
In addition to the primary objective stated above, secondary
objectives relate to assessing the cost-effectiveness of NOACs
stratified by center-specific TTR, age, and CHADS2 score.
Type of Economic Evaluation
Analysis was a cost-utility analysis with cost-effectiveness
assessed by the incremental cost per quality-adjusted life-year
(QALY) gained [13]. Sensitivity analysis was conducted by using
the incremental cost per life-year gained. Analysis adopts a third-
party payer perspective relating to a provincial ministry of health.
Target Population
The target population for the economic analysis was Canadians
with nonvalvular AF requiring anticoagulation. For the base-case
analysis, a typical patient profile from the RE-LY randomized
controlled trial (RCT) was adopted: an average age of 72 years
with no previous stroke or myocardial infarction (MI) [14].
Sensitivity analysis was conducted by adopting alternate patient
profiles including data from the ARISTOTLE and ROCKET-AF trials
[15,16].
Treatments
Treatments compared were warfarin, dabigatran 150 mg twice
daily and 110 mg twice daily, rivaroxaban, and apixaban. BecauseFig. 1 – Schematic oof concerns about the use of dabigatran 150 mg in elderly
patients, a sensitivity analysis was conducted including an addi-
tional comparator: switching patients from the dabigatran 150
mg twice-daily dose to the 110 mg twice-daily dose from age 80
years onwards.
Model Structure
The analysis was conducted by developing a Markov cohort
model. The cohort was followed from initiation of pharmaco-
therapy to death while simulating the incidence of events
associated with the patient population. At each time point, a
proportion of the cohort can be in one of many health states that
relate to the potential events common in this patient group, the
treatment currently being received, and history with respect to
transient ischemic attack (TIA)/stroke (major or minor) and MI.
Specific events modeled were TIA, stroke (fatal, major or minor),
bleeding (fatal, intracranial hemorrhage [ICH], major non-ICH,
and minor), MI, pulmonary embolism (PE: fatal or nonfatal), and
death without an event. The probability that such events occur is
influenced by a number of factors including treatment and
patient characteristics (Fig. 1). Patients who experience a stroke,
major bleed, or ICH on treatment were assumed to continue with
aspirin treatment alone, although a sensitivity analysis was
conducted that assumed that patients would remain on therapy.
The relative efficacy of the newer anticoagulants versus warfarin
is assumed to continue for the duration of the patients’ lifetime
while they continue on therapy.
Time Horizon
Base-case analysis adopted a lifetime horizon (maximum of 40
years posttreatment initiation), with sensitivity analysis adopting
horizons of 20 years, 10 years, and 2 years (average duration off Markov Model.
Table 1 – Input parameters.
Parameters Base estimate Probability distribution Reference
Annual rates of events with warfarin
Stroke
Transient ischemic attack (TIA) 0.016 Beta (186, 11608) [14]
Intracranial hemorrhage (ICH) 0.008 Beta (99, 11695) [14]
Major bleeds
Minor bleeds 0.008 Beta (90, 11704) [14]
Myocradial infaction (MI) 0.033 Beta (386, 11408) [14]
Pulmonary embolism (PE) 0.164 Beta (1931, 9863) [14]
Nonvascular death 0.006 Beta (66, 11728) [14]
0.001 Beta (12, 11782) [14]
0.033 Beta (391, 11403) [14]
Event-related probabilities
Percentage of first strokes that are fatal 0.237 Beta (44, 142) [14]
Percentage of nonfatal first strokes that are major
Increased risk of subsequent strokes being fatal 0.333 Beta (39, 78) [14]
Probability major bleed or ICH is fatal
Probability MI is fatal 1.57 Log normal (1.21, 2.03) [17]
Probability PE is fatal
0.084 Beta (40, 436) [14]
0.121 Beta (8, 58) [14]
0.333 Beta (4, 8) [14]
Event rate adjustments
Increase in stroke for each 10-y age increment 1.5 Log normal (1.30, 1.70) [18]
Increase in stroke given previous stroke/TIA
Increase in MI given previous MI 2.2 Log normal (0.78, 6.35) [19]
Increase in bleeding given age over 65 y
Increase in death given previous stroke 2.04 Log normal (1.17, 3.55) [20]
Increase in death given atrial fibrillation (AF) 2.66 Log normal (1.33, 5.32) [21]
Log normal (2.00, 2.70)
2.3 [22]
Log normal (1.04, 1.40)
1.2 [23]
Relative risks for aspirin vs. warfarin
Stroke
MI 1.62 Log normal (0.99, 2.65) [11]
ICH 1.42 Log normal (0.84, 2.39) [11]
Minor bleed 0.51 Log normal (0.16, 1.60) [11]
Major bleed 0.63 Log normal (0.32, 1.22) [11]
TIA 1.14 Log normal (0.47, 2.73) [11]
1.56 Log normal (0.86, 2.83) [11]
Odds ratios for apixaban vs. warfarin [12]
Stroke
MI 0.79 Log normal (0.65, 0.95)
ICH 0.88 Log normal (0.66, 1.17)
Major bleed 0.42 Log normal (0.30, 0.58)
0.8 Log normal (0.68, 0.94)
Odds ratios for dabigatran 110 mg vs. warfarin [12]
Stroke
MI 0.92 Log normal (0.74, 1.13)
ICH 1.32 Log normal (0.97, 1.78)
Major bleed 0.29 Log normal (0.19, 0.45)
0.94 Log normal (0.93, 1.26)
Odds ratios for dabigatran 150 mg vs. warfarin [12]
Stroke
MI 0.64 Log normal (0.51, 0.81)
ICH 1.29 Log normal (0.95, 1.75)
Major bleed 0.41 Log normal (0.28, 0.60)
1.08 Log normal (0.81, 1.10)
Odds ratios for rivaroxaban vs. warfarin [12]
Stroke
MI 0.83 Log normal (0.68, 1.02)
ICH 0.8 Log normal (0.61, 1.04)
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Table 1 – continued
Parameters Base estimate Probability distribution Reference
Major bleed 0.65 Log normal (0.46, 0.91)
1.14 Log normal (0.97, 1.33)
Utility values
Long-term utilities
AF 0.81 Beta (33.82, 7.93) [24]
Previous major stroke
Rankin score 3–4 0.39 Beta (69.74, 109.08) [25]
Rankin score 5 0.11 Beta (18.93, 153.16) [25]
Probability major stroke is 5 0.205 Beta (8, 39) [14]
Previous minor stroke
Previous ICH 0.75 Beta (86.69, 28.90) [25]
Previous MI (decrement) 0.75 Beta (86.69, 28.90) [25]
Decrement per year over 70 y 0.012 Normal (0.012, 0.0002) [24]
0.00029 Normal (0.00029, 0.00002) [24]
Decrements associated with events
MI
Major bleeds 0.125 Normal (-0.125, 0.009) [24]
Minor bleeds 0.092 Normal (-0.092, 0.010) [7]
PE 0.013 Normal (-0.013, 0.001) [7]
TIA 0.022 Normal (-0.022, 0.003) [26]
0.103 Normal (-0.103, 0.008) [24]
Costs ($)
Drug treatment (per annum)
Warfarin 5 mg daily
INR monitoring (per annum) for warfarin 54.61 Fixed [27]
Aspirin enteric coated 325 mg daily 240.69 Fixed [28]
Dabigatran 110 mg bid
Dabigatran 150 mg bid 39.04 Fixed [27]
Rivaroxaban 20 mg daily
Apixaban 5 mg bid 1,289.44 Fixed [27]
1,289.44 Fixed [27]
1,147.53 Fixed [27]
1,289.44 Fixed y
Events
Fatal stroke 16,800 Gamma (16.0, 1050.0) [11]
Minor stroke 16,800 Gamma (16.0, 1050.0) [11]
Major stroke 56,864 Gamma (16.0, 3554.0) [11]
TIA 4,296 Gamma (16.0, 268.5) [29]
ICH 16,559 Gamma (16.0, 1035.0) [11]
Major bleed 4,392 Gamma (16.0, 274.5) [11]
Minor bleed 104 Gamma (6.4, 16.3) [30]
Fatal MI 7,351 Gamma (16.0, 459.5) [11]
Nonfatal MI 11,380 Normal (11380.0, 167.0) [31]
PE 7,442 Normal (7442.0, 7682.1) [32]
Long-term costs (per annum)
MI 3,272 Gamma (190.6, 17.2) [11]
Major stroke 19,069 Gamma (16.0, 1191.8) [11]
Minor stroke 7,896 Gamma (16.0, 493.5) [31]
ICH 7,896 Gamma (16.0, 493.5) [31]
bid, twice a day; INR, international normalized ratio.
 Transition probabilities were characterized by beta distributions. Relative risks and odds ratios were characterized by log normal
distributions. Utility values for long-term states were characterized by beta distributions while utility decrements were characterized by
normal distributions. Costs were characterized by gamma distributions except where the coefficient of variation was low (o5%) where a
normal distribution was used. Drug costs were assumed fixed. For event costs where no measures of dispersion were available, a coefficient of
variation of 25% was assumed. Beta distributions are specified by alpha and beta, and log normal distributions are specified by lower and
upper limits of the 95% confidence intervals. Gamma distributions are specified by shape and scale parameters. Normal distributions are
specified by mean and standard error.
y Unknown—assumed to be equal to costs of dabigatran.
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 8 – 5 0 6502major clinical trials). A cycle length of 3 months was adopted,
with sensitivity analysis using cycle lengths of 1 month, 6
months, and 1 year. Future events were discounted at a rate of
5% per annum, with sensitivity analysis using rates of 0% and 3%.
Efficacy, Safety, and Adverse Events
The baseline estimates for the annual rates of clinical events on
warfarin and the probability that events were fatal were obtained
from the RE-LY RCT (Table 1) [14]. Sensitivity analysis adopted
warfarin event rates from other major RCTs to assess the impact
on results. No differences in event fatality rates between treat-
ments were assumed. For incorporation into the economic
model, transition probabilities for the duration of cycle length
were obtained by using standard methodology.
The estimate for the transition probability for each event for
dabigatran, apixaban, and rivaroxaban was derived by using the
odds ratio for each treatment obtained from a network meta-
analysis. A detailed description of the methods and results of the
network meta-analysis are available elsewhere [12]. Based on the
available results, the following events were modeled to vary by
anticoagulant: stroke, MI, major bleeds, and ICH. In addition, the
model incorporated the same risks of minor bleeds, PE, and TIA
for all anticoagulants. Sensitivity analyses were conducted incor-
porating the relative risks of minor bleeds and nonvascular
deaths.
Utility Values
Utility values were based on whether the patients experienced an
event (MI, stroke, PE, TIA, ICH, and extracranial hemorrhage) in
the current cycle and their event history (previous MI or stroke).
Utility values were sourced from published data (Table 1)
[7,24–26,33]. Analysis assumed no difference in utility values on
treatment. Sensitivity analysis assumed reduced utility on war-
farin and other anticoagulants as per previous studies [7,24,25].
Costs
Costs for all resources were adjusted to 2011 Canadian dollars by
using the Bank of Canada Inflation Calculator [34]. Drug costs
were obtained from the Ontario Drug Benefit formulary or from
the drug manufacturer [27]. Because no drug costs were available
for apixaban at the time of the analysis, the costs were assumed
to equal the drug costs for dabigatran. For each drug therapy,
annual drug treatment costs include a $7 prescription fee (every 3
months) and an 8% pharmacist’s markup. For warfarin, an addi-
tional cost of international normalized ratio monitoring was
added [28]. The costs of events and any associated long-termTable 2 – Base results.
Cost ($) QALYs
vs.
Warfarin 18,620 6.480
Dabigatran 150 mg 21,486 6.617
Dominated therapies
Apixaban 21,966 6.617
Rivaroxaban 22,016 6.541
Dabigatran 110 mg 22,804 6.543
Note. Dominated ¼ more costly and equal or fewer QALYs; Extended dom
treatment.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-yecare were obtained from the most recently available Canadian
sources (Table 1) [11,29–32,35]. In sensitivity analyses, costs were
increased and decreased by 50%.
Deterministic Sensitivity Analysis
Awide range of univariate sensitivity analyses were conducted to
test the effect of changes in underlying parameter values and
assumptions within the models. An Online Appendix in Supple-
mental Materials found at doi: 10.1016/j.jval.2013.01.009 details
the range and results of these analyses.
Threshold Analysis
Threshold analysis was conducted to assess the value of a
parameter required to lead to change in the interpretation of
the base result. This was based on assuming a willingness-to-pay
value of $50,000 for a QALY. Analysis was conducted for param-
eters for which there was limited information: that is, the price of
apixaban and the consequences of minor and major bleeds with
dabigatran.
Probabilistic Sensitivity Analysis
Probabilistic sensitivity analysis was conducted by using a Monte
Carlo simulation [29]. For the Monte Carlo simulation, probability
distributions related to natural history parameters, relative risks
and odds ratios, costs, and utilities were incorporated into the
analysis. Analysis adopted standard methods for defining uncer-
tainty around parameters (Table 1). Estimates of incremental
costs and QALYs were obtained by re-running the model employ-
ing values from the related probability distributions. In this study,
5000 replications were conducted; that is, a set of 5000 outcome
estimates was obtained. Cost-effectiveness acceptability curves
that present the probability that each treatment is optimal given
different values of willingness to pay for an additional QALY were
derived [36].
Analysis of Variability
Stratified analyses were conducted to assess the sensitivity of the
results to changes in the underlying patient population. Stratified
analyses incorporated, where possible, different warfarin-related
event rates based on the patient profile and available data. In
addition, where possible, different estimates of the relative
treatment effect of the newer oral anticoagulants compared with
warfarin were included. Analyses were conducted to stratify
patient by three criteria: CHADS2 score, age, and center’s TTR.Incremental cost per QALY gained (ICER) ($)
warfarin Sequential ICER
20,797 20,797
24,312 Dominated by dabigatran 150 mg
55,757 Dominated by dabigatran 150 mg and apixaban
66,354 Dominated by dabigatran 150 mg and apixaban
inance ¼ the combination of two other alternatives dominates the
ar.
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receiving warfarin.Results
Base-Case Analysis
Treatment with dabigatran 110 mg ($22,804) is more costly than
with rivaroxaban ($22,016), apixaban ($21,966), dabigatran 150 mg
($21,486), and warfarin ($18,620). For dabigatran 150 mg, treat-
ment costs were the greatest component of costs (Table 2). For all
other treatments, stroke-related costs were the greatest cost
component.
Dabigatran 150 mg and apixaban were the most effective
treatments in terms of QALYs (6.617). Dabigatran 110 mg (6.543)
and rivaroxaban (6.541) also produce more QALYs than warfarin
but fewer than dabigatran 150 mg and apixaban.
The incremental cost per QALY gained (ICUR) for dabigatran
150 mg versus warfarin was $20,797. Because dabigatran 110 mg,
apixaban, and rivaroxaban were more expensive and produced
less or equal QALYs, they were all dominated by dabigatran
150 mg.
Deterministic Sensitivity Analysis
The Online Appendix provides the results of the detailed uni-
variate sensitivity analysis. The interpretation of the results was
generally robust with the exception of the following.
Results were sensitive to the drug costs of apixaban. With a
10% reduction in the price of apixaban, apixaban would be cost-
effective assuming a maximum willingness-to-pay value of at
least $18,077 for a QALY. If the cost of apixaban was reduced by
20% to $2.56 per tablet, apixaban would be cost-effective assum-
ing a maximum willingness-to-pay value of at least $11,742 for
a QALY.
Results were very sensitive to the time horizon adopted. With
a time horizon of 10 years, the ICUR for dabigatran versus that for
warfarin was $50,455. With a time horizon of 2 years (the typical
duration of the RCTs considered within the network meta-
analysis), apixaban produced more QALYs than did dabigatran
150 mg but the ICUR compared with that for warfarin was
$362,797.
If the relative effects of treatments on nonvascular deaths
were included, rivaroxaban would be optimal as the ICUR for
rivaroxaban versus that for warfarin was $8278.
If treatment discontinuations not related to vascular events
were included in the analysis, apixaban produced more QALYs0%
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Fig. 2 – Cost-effectiveness Acceptability Curve.than did dabigatran 150 mg with an ICUR compared with that of
warfarin of $21,911.
In the analysis comparing switching patients from dabigatran
150 mg to dabigatran 110 mg at age 80 years to staying on
dabigatran, staying on dabigatran 150 mg was more cost-effective.
If patients had a previous major stroke, the incremental cost
per QALY for all treatments relative to warfarin increased; the
ICUR for dabigatran 150 mg versus that for warfarin was $144,801.
Threshold Analyses
Threshold analysis assumed a willingness-to-pay value of
$50,000 per QALY gained.
If the cost and disutility associated with major and minor
bleeds for dabigatran were 38% higher than estimated, apixaban
would be cost-effective. Apixaban would be more cost-effective
than dabigatran 150 mg if the price of apixaban was less than
$3.01 per tablet. Rivaroxaban would be cost-effective if the price
was lowered to $1.10 per tablet.
Probabilistic Sensitivity Analysis
The probabilistic sensitivity analysis highlights the uncertainty
around conclusions relating to cost-effectiveness (Fig. 2). At a
willingness-to-pay value of $50,000 for a QALY, dabigatran 150 mg
was the optimal treatment in 50.8% of the replications, apixaban
in 44.1%, rivaroxaban in 2.1%, dabigatran 110 mg in 1.6%, and
warfarin in 1.4%. Results were similar for all values of l from
$40,000 to $100,000.
Analysis of Variability
Table 3 provides detailed results of the analysis by variability.
Results were very sensitive to patient’s baseline CHADS2 score.
Based on a threshold of $50,000 per QALY gained, dabigatran 150
mg was optimal if the CHADS2 score was less than 2 or more than
2 with previous minor stroke. Apixaban would be optimal if the
CHADS2 score was 2 or more with no previous stroke.
Based on a threshold of $50,000, dabigatran 150 mg was
optimal for patients aged younger than 60 and 70 years and
apixaban was optimal for those aged 80 years.
In centers in which the TTR was less than 66%, dabigatran 150
mg would be optimal based on a threshold of $50,000. In centers
in which the TTR was 66% or more, apixaban would be optimal.Discussion
In the base-case analysis, dabigatran 150 mg was likely to be the
optimal treatment choice assuming that a decision maker was
willing to pay at least $20,797 per QALY. However, the conclusions
are uncertain given that apixaban was associated with equal
QALYs at only a slightly higher cost. The results of the proba-
bilistic analysis illustrate this further in that the probability that
dabigatran was optimal was no higher than 51%. Results were
insensitive to many of the parameter assumptions within the
model except for the cost of apixaban and the costs and
consequences from minor and major bleeds with dabigatran.
The results need to be placed in context with recent studies in
this area. Five separate analyses of the cost-effectiveness of
dabigatran versus warfarin in patients with nonvalvular AF have
been published [7–11,37]. All studies were heavily reliant on
clinical data from the RE-LY clinical trial and adopted Markov
models of similar format. No studies of the cost-effectiveness of
rivaroxaban or apixaban in this population have been published.
Similar to our study, a UK study funded by the Medical Research
Council found that dabigatran would not be cost-effective in
centers in which patients achieved good therapeutic control
Table 3 – Results of stratified analysis.
By CHADS2
score
Cost
($)
QALYs Incremental cost per QALY gained (ICER) ($)
vs.
warfarin
Sequential ICER
CHADS2 scoreo2
Warfarin 16,046 7.004
Dabigatran
150 mg
20,112 7.163 25,570 25,570
Dabigatran
110 mg
21,947 7.050 129,575 Dominated by dabigatran 150 mg and apixaban
Apixaban 21,052 7.117 44,289 Dominated by dabigatran 150 mg
CHADS2 score ¼ 2
Warfarin 15,317 6.084
Dabigatran
150 mg
18,694 6.202 28,407 28,407
Apixaban 18,916 6.207 29,156 48,588
Dabigatran
110 mg
19,589 6.152 62,432 Dominated by dabigatran 150 mg, rivaroxaban, and apixaban
Rivaroxaban 18,615 6.154 46,575 Extendedly dominated by apixaban and warfarin and dabigatran 150 mg and
warfarin
CHADS2 score42 (no previous stroke)
Warfarin 23,447 6.548
Dabigatran
150 mg
25,183 6.730 9,559 9,559
Apixaban 25,587 6.739 11,225 44,687
Dabigatran
110 mg
26,394 6.661 26,090 Dominated by rivaroxaban, dabigatran 150 mg, and apixaban
Rivaroxaban 25,719 6.667 19,035 Dominated by dabigatran 150 mg and apixaban
CHADS2 score42 (with previous minor stroke)
Warfarin 73,537 4.448
Dabigatran
150 mg
75,392 4.635 9,944 9,944
Apixaban 76,171 4.612 16,108 Dominated by dabigatran 150 mg
Dabigatran
110 mg
77,195 4.534 42,592 Dominated by rivaroxaban, dabigatran 150 mg, and apixaban
Rivaroxaban 75,610 4.569 17,121 Dominated by dabigatran 150 mg and extendedly dominated by apixaban and
warfarin
CHADS2 score4 2 (with previous major stroke)
Warfarin 134,943 2.153
Dabigatran
150 mg
140,566 2.200 121,905 121,905
Apixaban 140,734 2.199 126,252 Dominated by dabigatran 150 mg
Dabigatran
110 mg
140,270 2.177 222,599 Dominated by rivaroxaban and dabigatran 150 mg and extendedly dominated by
apixaban and warfarin
Rivaroxaban 139,434 2.184 145,146 Dominated by dabigatran 150 mg and extendedly dominated by apixaban and
warfarin
Notes. Dominated ¼ more costly and less QALYs; Extended dominance ¼ the combination of two other alternatives dominates the treatment.
Risk reductions relative to warfarin are specific to CHADS2 score for stroke and major bleeds and are for the complete RE-LY trial population
for all other events. Warfarin event rates are specific to CHADS2 for stroke, major bleed, ICH, and nonvascular deaths and for the complete RE-
LY trial population for all other events. For rivaroxaban, there were no available data for the risk reduction for stroke with CHADS2 score of less
than 2.
ICER, incremental cost-effectiveness ratio; ICH, intracranial hemorrhage; QALY, quality-adjusted life-year.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 8 – 5 0 6504(average TTR4 66%) [9]. In a Canadian study funded by the
manufacturer, dabigatran was found to have an incremental cost
per QALY gained compared with warfarin of Can $10,440 [11].
This finding is consistent with a US study that found that the
incremental cost per QALY gained from dabigatran versus war-
farin based on RE-LY trial population was US $12,386 when
reanalyzed based on actual drug price [7,37]. However, another
US study found differing results in that the incremental cost per
QALY gained from dabigatran versus warfarin based on RE-LY
trial population was US $86,000 [10].
In the most recent US study, dabigatran 150 mg was found to
be cost-effective when compared with warfarin in patients withprevious stroke or TIA: incremental cost per QALY gained of
$25,000 [8]. It is not possible, however, to critically appraise this
study because it was published providing only limited details of
methodology and no statement of funding.
In our analysis, rivaroxaban was optimal only when the
relative effects of treatment on nonvascular deaths were included.
What constituted a nonvascular death, however, may have dif-
fered across the trials. In addition, the odds ratio for rivaroxaban
for reducing nonvascular death is superior to the odds ratio for
reduction in stroke questioning the relevance of this outcome.
Results varied by a center’s average TTR, a patient’s CHADS2
score, and patient age. In centers with good control, apixaban
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 8 – 5 0 6 505would be optimal while in centers with poorer control, dabiga-
tran would be optimal. Dabigatran 150 mg is likely to be optimal
for patients with a CHADS2 score of less than 2 and more than 2
with previous minor stroke. Apixaban is likely to be optimal for
patients with a CHADS2 score of 2 or more without previous
stroke. Dabigatran 150 mg is optimal for patients younger than 75
years while apixaban is optimal for patients aged 75 years or
more. None of the new anticoagulants would be cost-effective if
patients had a previous major stroke, which is due to the reduced
utility value for patients with a previous major stroke (0.33) and
the high long-term care costs for these patients.
There are a number of limitations to this study. No head-to-
head studies have been conducted comparing newer oral anti-
coagulants. As a consequence, economic analysis was based on
indirect comparisons using network meta-analysis. This
requires that clinical and methodological variation across stud-
ies be minimized. The small number of trials limited the ability
to adjust for heterogeneity using other techniques such as
meta-regression or sensitivity analysis. The limited follow-up
from the clinical trials and the sensitivity of results to the
duration of treatment effect lead to uncertainty around whether
the new anticoagulants will be cost-effective in the long term.
With a time horizon of 10 years, dabigatran would be cost-
effective only if a decision maker was willing to pay $50,455 per
QALY. If analysis was restricted to 2 years—the typical follow-up
period within the major clinical trials—both apixaban and
rivaroxaban were dominated and dabigatran 150 mg would be
cost-effective only if a decision maker was willing to pay more
than $335,542 per QALY. Thus, the lack of information regarding
the long-term harms and benefits of new anticoagulants beyond
the clinical trial follow-up period warrants cautious consider-
ation and emphasizes the need for further research.
The lack of further data on the consequences of major bleeds
with dabigatran does limit the results. Analysis identified how
sensitive results were to this, with apixaban being favored if the
costs and disutilities associated with bleeds with dabigatran were
38% greater than for other anticoagulants.
The lack of price for apixaban makes any inferences regarding
its cost-effectiveness dependent on the actual price. If apixaban
costs 6% per day less than does dabigatran, then it would be both
equally effective and equally costly. Any negotiated price reduc-
tion for dabigatran, however, would also increase its probability
to be cost-effective. However, a substantive price reduction of
greater than 60% for rivaroxaban would be required to affect the
conclusions of the analysis.
In conclusion, the results of the cost-effectiveness analysis
were highly sensitive to the patient population under consider-
ation. Rivaroxaban and dabigatran 110 mg were unlikely to be
cost-effective. In different scenarios, apixaban or dabigatran 150
mg were optimal. Thus, the choice between these two options
may come down to the price of apixaban and further evidence on
the impact of major and minor bleeds with dabigatran.
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